Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Eur Radiol ; 27(10): 4316-4323, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28401339

ABSTRACT

OBJECTIVE: To correlate the R2* value obtained by iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL) with fibrotic focus (FF), microvessel density and hypoxic biomarker (HIF-1α) in breast carcinoma. METHODS: Forty-two patients who were diagnosed with invasive ductal carcinoma (IDC) of the breast underwent breast MRI including IDEAL before surgery. The entire region of interest (ROI) was delineated on the R2* map, and average tumour R2* value was calculated for each ROI. Histological specimens were evaluated for the presence of FF, the microvessel density (the average microvessel density and the ratio of peripheral to central microvessel density), and the grading of HIF-1α. RESULTS: FF was identified in 47.6% (20/42) of IDCs. Average R2* value for IDC with FF (42.4±13.2 Hz) was significantly higher than that without FF (28.5±13.9 Hz) (P = 0.01). Spearman rank correlation suggested that the average R2* value correlated with the grade of HIF-1α and the ratio of peripheral to central microvessel density for IDCs (P < 0.001). CONCLUSION: Quantification of tumour R2* using IDEAL is associated with the presence of FF and the overexpression of HIF-1α, and may therefore be useful in predicting hypoxia of breast carcinoma. KEY POINTS: • R2* value obtained by IDEAL correlates with the overexpression of HIF-1α. • R2* value obtained by IDEAL is associated with fibrotic focus. • R2* quantification may be useful in predicting hypoxia of breast carcinoma.


Subject(s)
Breast Neoplasms/diagnostic imaging , Carcinoma, Ductal/diagnostic imaging , Magnetic Resonance Imaging/methods , Adipose Tissue , Adult , Aged , Biomarkers, Tumor/analysis , Breast Neoplasms/blood supply , Breast Neoplasms/pathology , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/pathology , Female , Fibrosis , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Least-Squares Analysis , Prognosis , Retrospective Studies , Water
2.
Proc Natl Acad Sci U S A ; 106(9): 3372-7, 2009 Mar 03.
Article in English | MEDLINE | ID: mdl-19218449

ABSTRACT

Epithelial-stromal cell interactions have an important role in breast tumor progression, but the molecular mechanisms underlying these effects are just beginning to be understood. We previously described that fibroblasts promote, whereas normal myoepithelial cells inhibit, the progression of ductal carcinoma in situ (DCIS) to invasive breast carcinomas by using a xenograft model of human DCIS. Here, we report that the tumor growth and progression-promoting effects of fibroblasts are at least in part due to increased COX-2 expression in tumor epithelial cells provoked by their interaction with fibroblasts. Up-regulation of COX-2 in DCIS xenografts resulted in increased VEGF and MMP14 expression, which may contribute to the larger weight and invasive histology of COX-2-expressing tumors. Administration of celecoxib, a selective COX-2 inhibitor, to tumor-bearing mice decreased xenograft tumor weight and inhibited progression to invasion. Coculture of fibroblasts with DCIS epithelial cells enhanced their motility and invasion, and this change was associated with increased MMP14 expression and MMP9 protease activity. We identified the NF-kappaB pathway as one of the mediators of stromal fibroblast-derived signals regulating COX-2 expression in tumor epithelial cells. Inhibition of NF-kappaB and COX-2 activity and down-regulation of MMP9 expression attenuated the invasion-promoting effects of fibroblasts. These findings support a role for COX-2 in promoting the progression of DCIS to invasive breast carcinomas, and suggest that therapeutic targeting of the NF-kappaB and prostaglandin signaling pathways might be used for the treatment and prevention of breast cancer.


Subject(s)
Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Carcinoma, Ductal/enzymology , Carcinoma, Ductal/pathology , Cyclooxygenase 2/metabolism , Epithelial Cells/enzymology , Stromal Cells/enzymology , Animals , Breast Neoplasms/blood supply , Breast Neoplasms/drug therapy , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/drug therapy , Cell Communication , Cell Line, Tumor , Cyclooxygenase 2 Inhibitors/therapeutic use , Disease Models, Animal , Disease Progression , Female , Humans , Mice , Mice, Nude , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Neoplasm Invasiveness/pathology , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
3.
J Hepatobiliary Pancreat Surg ; 15(3): 322-6, 2008.
Article in English | MEDLINE | ID: mdl-18535772

ABSTRACT

BACKGROUND/PURPOSE: When a pancreatoduodenectomy is to be conducted, preoperative understanding of the vascular anatomy of the pancreatic head is important in order to reduce intraoperative bleeding. Using multislice computed tomography (MS-CT), we investigated the depiction rate and branching of the inferior pancreaticoduodenal artery (IPDA) and dorsal pancreatic artery (DPA), afferent arteries to the pancreatic head. METHODS: In 109 patients (68 with pancreatic cancer, 21 with biliary tract cancer, 15 with intraductal papillary mucinous tumor of the pancreas, and 5 others), images were taken, using 64-row MS-CT, in the early and late arterial phases. RESULTS: The depiction rates were 98.2% for the IPDA and 96.3% for the DPA. Branching of the IPDA was categorized into three types: a type in which the IPDA formed a common vessel with the first jejunal branch (72.0%), a type in which the IPDA branched directly from the superior mesenteric artery (18.7%), and a type in which the anterior inferior pancreaticoduodenal artery (AIPDA) and posterior inferior pancreaticoduodenal artery (PIPDA) branched separately (9.3%). DPA branching was categorized into five types, in which the DPA branched from the splenic artery (40.0%), from the common hepatic artery (25.7%), from the superior mesenteric artery (20.0%), and from the celiac artery (8.6%), and a type in which the DPA branching did not follow any of the above patterns (5.7%). CONCLUSIONS: MS-CT images of vascular architecture enable evaluation from any angle, which is not possible with conventional angiography, making MS-CT a useful diagnostic imaging technique for understanding the vascular anatomy of the pancreatic head prior to conducting pancreatoduodenectomy for diseases of the pancreatic head region.


Subject(s)
Pancreas/blood supply , Tomography, X-Ray Computed/methods , Bile Duct Neoplasms/blood supply , Bile Duct Neoplasms/diagnostic imaging , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/diagnostic imaging , Carcinoma, Papillary/blood supply , Carcinoma, Papillary/diagnostic imaging , Humans , Pancreas/diagnostic imaging , Pancreatic Neoplasms/blood supply , Pancreatic Neoplasms/diagnostic imaging
4.
Anticancer Res ; 25(4): 3075-81, 2005.
Article in English | MEDLINE | ID: mdl-16080568

ABSTRACT

BACKGROUND: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. MATERIALS AND METHODS: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. RESULTS: Chemo- and/or endocrine therapy-naïve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the "natural history" of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. CONCLUSION: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.


Subject(s)
Bone Neoplasms/blood supply , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Adult , Aged , Bone Neoplasms/metabolism , Bone Neoplasms/therapy , Breast Neoplasms/metabolism , Breast Neoplasms, Male/metabolism , Breast Neoplasms, Male/pathology , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/metabolism , Carcinoma, Ductal/secondary , Carcinoma, Ductal/therapy , Cohort Studies , Female , Humans , Immunohistochemistry , Male , Middle Aged , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Retrospective Studies , Vascular Endothelial Growth Factor A/biosynthesis
5.
Clin Exp Metastasis ; 21(2): 107-18, 2004.
Article in English | MEDLINE | ID: mdl-15168728

ABSTRACT

Patients with breast cancer brain metastases cannot be cured and have a poor prognosis, with a median survival time of six months after diagnosis, despite developments in diagnostic and therapeutic modalities. In large part the progress in understanding the biology of breast cancer brain metastasis has been limited by the lack of suitable cell lines and experimental models. The objective of this study was to develop a reliable experimental model to study the pathogenesis of breast cancer brain metastases, using intra-internal carotid artery injection of breast cancer cells into nude mice. Brain metastasis-selected variant cells were recovered after three cycles of injection into the internal carotid artery of nude mice and harvest of brain metastases, resulting in variants termed MDA-231 BR1, -BR2 and -BR3. The metastasis-selected cells had increased potential for experimental brain metastasis and mice injected with these cells had significantly shorter mean survival than mice injected with the original cell line. Brain metastatic lesions of the selected variants contained significantly more CD31-positive blood vessels than metastases of the non-selected cell line. The variants selected from brain metastases released significantly more VEGF-A and IL-8 into culture supernatants than the original cell line, and more VEGF-A RNA when cultured in normoxic conditions. Mice injected with MDA-231 BR3 into the carotid artery were treated with the VEGF-receptor tyrosine kinase inhibitor PTK787/Z 222584. Oral administration of the inhibitor resulted in a significant decrease in brain tumor burden, reduced CD31-positive vessels in the brain lesions and incidence of PCNA positive tumor cells, and increased apoptosis in the tumor, as measured by TUNEL labeling. We conclude that elevated VEGF expression contributes to the ability of breast cancer cells to form brain metastases. Targeting endothelial cells with a VEGF-receptor specific tyrosine kinase inhibitor reduced angiogenesis and restricted the growth of the brain metastases.


Subject(s)
Brain Neoplasms/secondary , Breast Neoplasms/pathology , Carcinoma, Ductal/secondary , Vascular Endothelial Growth Factor A/physiology , Animals , Brain Neoplasms/blood supply , Brain Neoplasms/drug therapy , Breast Neoplasms/metabolism , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/drug therapy , Carcinoma, Ductal/metabolism , Carcinoma, Ductal/pathology , Carotid Artery, Internal , Cell Hypoxia , Cell Line, Tumor/metabolism , Cell Line, Tumor/pathology , Cell Line, Tumor/transplantation , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Female , Humans , Injections, Intra-Arterial , Interleukin-8/metabolism , Mice , Mice, Nude , Neoplasm Transplantation , Neovascularization, Pathologic/drug therapy , Phthalazines/pharmacology , Phthalazines/therapeutic use , Pyridines/pharmacology , Pyridines/therapeutic use , RNA, Messenger/biosynthesis , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor A/genetics , Xenograft Model Antitumor Assays
6.
AJR Am J Roentgenol ; 182(5): 1207-13, 2004 May.
Article in English | MEDLINE | ID: mdl-15100120

ABSTRACT

OBJECTIVE: The aim of our study was to evaluate the association of the vascularity of liver metastases, as characterized by MRI, and disease progression in breast cancer patients. MATERIALS AND METHODS: Sixteen breast cancer patients with liver metastases who underwent MRI before and after systemic therapy were retrospectively identified. On the basis of comparison of each MRI examination with the previous examination, disease status of the patients was classified as complete response, partial response, stable disease, or progressive disease. Liver metastases were characterized as hyper- or hypovascular on the basis of the degree of enhancement in the arterial, portal, and interstitial phases of imaging after administration of a contrast agent. Fisher's exact test and ordinal logistic regression models, including the type of systemic therapy, presence of multiple metastases, and hormone receptor status, were used to estimate the unadjusted and risk-adjusted association between the presence of hypervascular liver metastases and disease progression. RESULTS: All patients in our sample (n = 16) were women and most (12/16, 75%) were white. Their median age was 51.5 years. In unadjusted analyses, the association between the presence of hypervascular liver metastases and disease progression was statistically significant (p < 0.0001). In multiple logistic regression analyses, hypervascular liver metastases were found to be an independent predictor of disease progression. Patients with hypervascular liver lesions were 20.5 times more likely to experience disease progression than patients without hypervascular metastases (odds ratio, 20.5; 95% confidence interval, 5.1-83.5; p < 0.0001). CONCLUSION: Our analysis provides suggestive evidence that disease progression can be predicted through MRI assessment of the vascularity of liver metastases in patients with breast cancer.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/secondary , Liver Neoplasms/blood supply , Liver Neoplasms/secondary , Magnetic Resonance Imaging , Adult , Aged , Carcinoma, Ductal/pathology , Disease Progression , Female , Humans , Liver Neoplasms/pathology , Middle Aged , Predictive Value of Tests , Retrospective Studies
7.
Zhonghua Zhong Liu Za Zhi ; 26(11): 673-7, 2004 Nov.
Article in Chinese | MEDLINE | ID: mdl-15777506

ABSTRACT

OBJECTIVE: To investigate whether correlation exists between mRNA expression of IGF-II and hepatocyte growth factor (HGF) and tumor progression and prognosis in gastric cancer. METHODS: In situ hybridization technique was used to examine mRNA expression of IGF-II and HGF, and immunohistochemical technique was used to examine protein expression of CD34 in 105 specimens of gastric carcinoma. RESULTS: In situ hybridization revealed that the positive rates of IGF-II mRNA and HGFmRNA were 49.5% and 57.1%, respectively. In stage T3-T4 cases, positive mRNA expression rates of IGF-II and HGF, the frequencies of vessel invasion, lymph node metastasis and distant metastasis were significantly higher than those in stage T1-T2 cases. The mean microvascular density (MVD) in stage T3-T4 tumors, vessel invasion, lymph node metastasis and distant metastasis were significantly more frequent than those in stage T1-T2 tumors. The mean MVD in tumors with positive IGF-II and HGF expressions was significantly higher than that in tumors without IGF-II and HGF expression. There were positive correlations between MVD and expression of IGF-II and HGF. The mean survival time and 5-year survival rate in cases with positive IGF-II and HGF expression and MVD value > or = 39.5 were significantly shorter those that in cases with negative IGF-II and HGF expression and MVD value < 39.5. CONCLUSION: IGF-II and HGF promote angiogenesis in gastric cancer, and take part in tumor invasion and metastasis. They can be used as prognostic markers of gastric cancer in clinical practice.


Subject(s)
Carcinoma, Ductal/metabolism , Hepatocyte Growth Factor/biosynthesis , Insulin-Like Growth Factor II/biosynthesis , Neovascularization, Pathologic , Stomach Neoplasms/metabolism , Adenocarcinoma, Papillary/blood supply , Adenocarcinoma, Papillary/metabolism , Adenocarcinoma, Papillary/secondary , Adult , Aged , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/secondary , Carcinoma, Signet Ring Cell/blood supply , Carcinoma, Signet Ring Cell/metabolism , Carcinoma, Signet Ring Cell/secondary , Disease Progression , Female , Hepatocyte Growth Factor/genetics , Humans , Insulin-Like Growth Factor II/genetics , Liver Neoplasms/blood supply , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Lymphatic Metastasis , Male , Microcirculation , Middle Aged , Neoplasm Invasiveness , Peritoneal Neoplasms/blood supply , Peritoneal Neoplasms/metabolism , Peritoneal Neoplasms/secondary , Prognosis , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Stomach Neoplasms/blood supply , Stomach Neoplasms/pathology , Survival Rate
8.
Breast Cancer ; 10(4): 312-9, 2003.
Article in English | MEDLINE | ID: mdl-14634509

ABSTRACT

BACKGROUND: Although the prognostic value of microvessel density (MVD) has been studied in breast cancer, the results still remain controversial. PATIENTS AND METHODS: Paraffin embedded sections of invasive ductal carcinoma of the breast were immunohistochemically stained for factor VIII- related antigen in 252 patients with a median follow-up duration of 7.0 years. MVD quantification of the three most vascular areas at a magnification of x 200 was performed. RESULTS: The 252 patients were stratified into high and low MVD groups according to a cut-off value that was the upper one-third MVD value of all patients. The patients with a high MVD had a significantly worse outcome in terms of both disease free survival (DFS) (p< 0.0001) and overall survival (OS) (p= 0.0012) compared with those with a low MVD. The same effects were seen in patients with lymph node negative as well as positive breast cancer. Multivariate analyses indicated the nodal status, nuclear grade and MVD (p= 0.0001) to be independent prognostic factors for the DFS, while the nodal status, estrogen receptor status, tumor size and MVD (p= 0.0006) were independent prognostic factors for the OS. CONCLUSION: MVD was found to be an independent prognostic indicator of recurrence and death for breast cancer, and is therefore considered to be a useful factor for selecting high risk patients to receive adjuvant therapies.


Subject(s)
Breast Neoplasms/blood supply , Carcinoma, Ductal/blood supply , Adult , Aged , Aged, 80 and over , Analysis of Variance , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal/secondary , Carcinoma, Ductal/therapy , Disease-Free Survival , Female , Humans , Immunohistochemistry , Male , Microcirculation , Middle Aged , Predictive Value of Tests , Prognosis , Recurrence
9.
J Magn Reson Imaging ; 18(4): 467-77, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14508784

ABSTRACT

PURPOSE: To investigate the association between parameters obtained from dynamic contrast enhanced MRI (DCE-MRI) of breast cancer using different analysis approaches, as well as their correlation with angiogenesis biomarkers (vascular endothelial growth factor and vessel density). MATERIALS AND METHODS: DCE-MRI results were obtained from 105 patients with breast cancer (108 lesions). Three analysis methods were applied: 1) whole tumor analysis, 2) regional hot-spot analysis, and 3) intratumor pixel-by-pixel analysis. Early enhancement intensities and fitted pharmacokinetic parameters were studied. Paraffin blocks of 71 surgically resected specimens were analyzed by immunohistochemical staining to measure microvessel counts (with CD31) and vascular endothelial growth factor (VEGF) expression levels. RESULTS: MRI parameters obtained from the three analysis methods showed significant correlations (P < 0.0001), but a substantial dispersion from the linear regression line was noted (r = 0.72-0.97). The entire region of interest (ROI) vs. pixel population analyses had a significantly higher association compared to the entire ROI vs. hot-spot analyses. Cancer specimens with high VEGF expression had significantly higher CD31 microvessel densities than did specimens with low VEGF levels (P < 0.005). No significant association was found between MRI parameters obtained from the three analysis strategies and IHC based measurements of angiogenesis. CONCLUSION: A consistent analysis strategy was important in the DCE-MRI study. In this series, none of these strategies yielded results for MRI based quantitation of tumor vascularity that were associated with IHC based measurements. Therefore, different analyses could not account for the lack of association.


Subject(s)
Breast Neoplasms/pathology , Breast/pathology , Neovascularization, Pathologic , Vascular Endothelial Growth Factor A/metabolism , Breast/blood supply , Breast Neoplasms/blood supply , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/pathology , Carcinoma, Lobular/blood supply , Carcinoma, Lobular/pathology , Contrast Media , Female , Gadolinium DTPA , Humans , Immunohistochemistry , Linear Models , Middle Aged , Platelet Endothelial Cell Adhesion Molecule-1
10.
Histopathology ; 43(3): 244-53, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12940777

ABSTRACT

AIMS: To compare correlations between different morphometrically assessed measurements of tumour microvasculature and to identify those which show closest correlation with Ki67 and to examine radial intratumoral distribution of microvessels and proliferation. METHODS AND RESULTS: Immunohistochemically defined microvessels and Ki67+ cells were quantified in sequential fields of 0.12 mm2 (x600) in four transects in each of five tumours. The total number of vessels (TNV) correlated more closely with proliferative activity than the numbers of vessels with a discernible lumen (TLV) and TNV decreased towards the centre of the tumour whereas TLV did not. A higher proliferative index (PI) was found at the periphery of the tumours. Comparison between transects through subjectively identified microvessel hot-spots and non-hot-spot transects showed similar mean, median and peak vessel counts but showed a different distribution on chi2 analysis. CONCLUSIONS: TNV correlates most closely with PI in breast carcinomas. There is marked variation in microvessel density and PI between fields of 0.12 mm2 but there is a significant radial reduction in both from the edge towards the centre of tumours.


Subject(s)
Breast Neoplasms/blood supply , Breast Neoplasms/pathology , Carcinoma, Ductal/blood supply , Carcinoma, Ductal/pathology , Antigens, CD34/metabolism , Breast Neoplasms/metabolism , Carcinoma, Ductal/metabolism , Humans , Immunohistochemistry , Ki-67 Antigen/metabolism , Neovascularization, Pathologic/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...